Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | KIF11 | P52732 | 10/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | HEXA | P06865 | 1/20 | 0.45 |
| ▸ | HEXB | P07686 | 1/20 | 0.45 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8990814 | 0.94 | MAOB (0.61) | MAOBKIF11TAAR1CHKAFDFT1 | |
| SCHEMBL91061 | 0.93 | TAAR1 (0.54) | MAOBKIF11TAAR1IDO1 | |
| Ammonia Solution, Strong SCHEMBL266277 | 0.91 | TAAR1 (0.52) | MAOBKIF11TAAR1IDO1 | |
| SCHEMBL31277159 | 0.86 | SRD5A2 (0.50) | MAOBKIF11TAAR1IDO1 | |
| SCHEMBL19010903 | 0.86 | TP53 (0.47) | MAOBKIF11TAAR1IDO1HEXA | |
| SCHEMBL13197394 | 0.85 | RXRA (0.59) | MAOBKIF11 | |
| SCHEMBL19301067 | 0.85 | KIF11 (0.52) | MAOBKIF11HEXAHEXBAGXT | |
| SCHEMBL24594088 | 0.84 | MAOB (0.41) | MAOBKIF11TAAR1FDFT1 | |
| SCHEMBL9074271 | 0.84 | MAOB (0.41) | MAOBKIF11TAAR1 | |
| SCHEMBL29124537 | 0.84 | TAAR1 (0.47) | MAOBKIF11TAAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340026-A1 | COMPOUNDS | NEW PHARMA LICENCE HOLDINGS LTD (MT) | 2023-10-26 | — | — | US | disclosed |
| US-20230302162-A1 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-09-28 | — | — | US | disclosed |
| US-11384060-B2 | Amide compounds and use thereof | ALPHALA CO., LTD. (TW) | 2022-07-12 | — | — | US | disclosed |
| EP-3452464-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-20190337915-A1 | AMIDE COMPOUNDS AND USE THEREOF | ALPHALA CO., LTD. (TW) | 2019-11-07 | — | — | US | disclosed |
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180030092-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2018-02-01 | — | — | US | disclosed |
| WO-2018010476-A1 | GLYCOPEPTIDES BASED DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海来益生物药物研究开发中心有限责任公司 | 2018-01-18 | — | — | WO | disclosed |
| WO-2018010475-A1 | GLYCOPEPTIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海来益生物药物研究开发中心有限责任公司 | 2018-01-18 | — | — | WO | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008116156-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS ASSOCIATED WITH MITOCHONDRIAL FUNCTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
| WO-2007053193-A2 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053725-A2 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| US-5292454-A | Trifluorotoluene compounds, and a liquid crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-03-08 | — | — | US | disclosed |
| WO-1990014404-A1 | TRIFLUOROTOLUOL COMPOUNDS AND LIQUID CRYSTALLINE MEDIUM | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | CCR7, ACKR3, CCR2 | MAOB 2710/4885KIF11 3750/4885TAAR1 195/4885 |
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | MAOB 1080/4885KIF11 3507/4885TAAR1 2334/4885 |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | MAOB 1894/4885KIF11 3486/4885TAAR1 684/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | MAOB 1654/4885KIF11 3992/4885TAAR1 163/4885 |
| US-20190337915-A1 | AMIDE COMPOUNDS AND USE THEREOF | GLP1R, IAPP, GPR119 | MAOB 2177/4885KIF11 3970/4885TAAR1 960/4885 |
| US-20230340026-A1 | COMPOUNDS | BCAT1, BCAT2, CCNT1 | MAOB 440/4885KIF11 3353/4885TAAR1 823/4885 |
| US-20180030092-A1 | COMPOUNDS | BCAT1, BCAT2, IL4I1 | MAOB 512/4885KIF11 3122/4885TAAR1 886/4885 |
| US-11384060-B2 | Amide compounds and use thereof | GLP1R, IAPP, GPR119 | MAOB 2177/4885KIF11 3970/4885TAAR1 960/4885 |
| US-20230302162-A1 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | PLA2G4B, PLA2G1B, PLA2G12B | MAOB 1032/4885KIF11 4787/4885TAAR1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.